Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476146 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL4250662 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL3643891 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL3552873 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL2995724 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL3554330 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL18591298 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL19219868 | 1.00 | PEPD (0.48) | PEPDXPNPEP1PTPN1MMP2ANPEP | |
| SCHEMBL29827776 | 0.91 | NR1H2 (0.39) | PEPDXPNPEP1PTPN1NR1H2NR1H3 | |
| SCHEMBL29947782 | 0.91 | NR1H2 (0.39) | PEPDXPNPEP1PTPN1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025106362-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4526300-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025026903-A1 | IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-4305038-B1 | KRAS G12D INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20080125589-A1 | Process for Production of Fluoro Derivative | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080114053-A1 | Method for Producing Fluorinated Proline Derivative | MITSUI CHEMICALS, INC. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080114053-A1 | Method for Producing Fluorinated Proline Derivative | MITSUI CHEMICALS, INC. (JP) | 2008-05-15 | — | — | US | disclosed |
| US-7279584-B2 | Method for production of cis-4-fluoro-L-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279584-B2 | Method for production of cis-4-fluoro-L-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125589-A1 | Process for Production of Fluoro Derivative | PFAS, PFKFB2, PFKFB1 | PEPD 3407/4885XPNPEP1 4402/4885PTPN1 4355/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | PEPD 2977/4885XPNPEP1 2128/4885PTPN1 2229/4885 |
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | PEPD 4331/4885XPNPEP1 3603/4885PTPN1 988/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | PEPD 4815/4885XPNPEP1 3047/4885PTPN1 987/4885 |
| US-20080114053-A1 | Method for Producing Fluorinated Proline Derivative | LPO, NPFFR1, NPFFR2 | PEPD 2007/4885XPNPEP1 1214/4885PTPN1 2372/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | PEPD 4765/4885XPNPEP1 4293/4885PTPN1 975/4885 |
| US-20060281927-A1 | Process for production of cis-4-fluoro-l-proline derivatives | PRAP1, P4HA1, SLC6A7 | PEPD 10/4885XPNPEP1 187/4885PTPN1 2933/4885 |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | PEPD 3930/4885XPNPEP1 1850/4885PTPN1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.